Endo International plc ("Endo") is an American Irish-domiciled generics and specialty branded pharmaceutical company.

According to the law firm press release, the Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Endo's arrangements with pharmacy benefit managers with respect to the migraine therapy Frova included questionable incentives intended to increase sales revenues; (ii) consequently, Endo’s revenues and revenue projections relied in part on unsustainable arrangements; and (iii) as a result of the foregoing, Defendants’ statements about Endo’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On August 19, 2016, the Court appointed Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on October 5, 2016.

A third amended Complaint was filed on November 16. Defendants filed a Motion to Dismiss the third amended Complaint on December 14, 2016. On January 16, 2018, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiff was not given leave to file an amended Complaint. On February 14, Plaintiff filed a Motion to alter judgment and for leave to amend. On April 27, the Court issued an Order denying Plaintiffs' motion for relief from the Court's judgment. On May 29, Plaintiffs filed a Notice appealing the decision of the Court. The Court of Appeals affirmed the District Court's Order on May 20, 2019.